Search

NiCo2O4, as a low‐cost and high‐performance binary transition metal oxide material, has been widely used in the fabrication of supercapacitor electrodes. However, the low energy density of binary metal oxides limits their large‐scale practical applications in supercapacitors, so it is highly desirable to design the structure of the NiCo2O4‐based supercapacitor. Therefore, in this paper, NiCo2O4 is compounded with polyaniline (PANI) to improve its electrochemical performance by exploiting the synergistic effect. The NiCo2O4@PANI composite electrode exhibits a specific capacitance of 561.2 F/g at 10 mV/s. In this study, asymmetric supercapacitors are assembled with NiCo2O4@PANI as the positive electrode and MXene as the negative electrode. The NiCo2O4@PANI‐CC//MXene‐CC supercapacitor has a specific capacitance of 31.95 F/g at a scan rate of 10 mV/s and a good cycle retention capacity of 86.2% after 3000 cycles. The excellent electrochemical performances are attributed to the dynamic equilibrium and fast redox kinetics of the two electrodes. [ABSTRACT FROM AUTHOR]

Improving the structure of electrode materials is an effective way to enhance the electrochemical properties of supercapacitors. Titanium carbide (TiC) is a two-dimensional transition metal carbide (MXene) that has been widely studied in the field. Laminating the MXene material with polypyrrole (PPy) not only prevents oxidation but also enhances the properties of the resulting electrode. Carbon cloth (CC) is chosen as the substrate to be loaded with the active material to provide remarkable flexibility. The CC/MXene-PPy electrode has a capacitance of 300.8 F g−1 at 1 A g−1. To obtain supercapacitors with higher energy density, MnO2 materials are attached to the CC surface by chemical deposition. Afterward, CC/MnO2 and CC/MXene-PPy separately as the positive and negative electrodes are assembled to form asymmetric supercapacitors. The device exhibits a capacitance value of 75.3 F g−1 at 10 mV s−1. The asymmetric supercapacitor demonstrates good cycling stability performance, with the capacitance remaining at 86.9% after 5000 cycles at 5 A g−1. Moreover, the asymmetric supercapacitors demonstrate remarkable flexibility performance, showcasing significant potential for the advancement of novel flexible devices. [ABSTRACT FROM AUTHOR]

Herein we described the clinical characteristics of a Chinese girl with youth-onset type 2 diabetes coexisting with FRG, in whom a novel mutation (NM 003041.4:c.1129 + 2 T > C) of the I SLC5A2 i gene might explain FRG occurrence. MODY is a special type of diabetes mellitus, representing a small but very important fraction of diabetic patients (1%-5%),[[4]] and 1%-6% of cases in pediatric age.[6] In this patient, no mutations in 14 genes associated with MODY have been detected, and its diagnosis was also excluded. The pathogenesis of youth-onset type 2 diabetes is different from that of maturity-onset diabetes of the young (MODY) and from type 1 diabetes, but there are many overlapped clinical manifestations among these three types of diabetes. A young-onset type 2 diabetic Chinese girl with familial renal glycosuria caused by a novel mutation in SLC5A2: A case report. [Extracted from the article]

The clear cell (CCC), high grade serous (HGSC) and endometrioid (EC) ovarian carcinomas share overlapping histological features. The oncogene IMP3 is implicated in CCC with an elusive utility in differential diagnosis. We collected 366 cases with ovarian primary carcinomas to detect IMP3, Napsin-A and HNF-1β by immunochemistry. In 351 cases, the positive expression rate of IMP3 in CCC was significantly higher than that either in EC or HGSC (p < 0.01). The sensitivity of IMP3 in CCC was higher than Napsin-A but lower than HNF-1β (p < 0.01). The specificity of IMP3 in CCC was lower than Napsin-A but higher than HNF-1β (p < 0.01). The composite markers Napsin-A+/IMP3+ and the IMP3+/HNF-1β+/Napsin-A+ offered the highest odds ratio (p < 0.001), the highest specificity, the highest positive predictive value and the highest positive likelihood ratio. The ROC analysis showed that the combination of Napsin-A, HNF-1β and IMP3 offered the biggest AUC compared with either the singular marker performances or the other binary combinations (p < 0.001). In 15 cases of EC mixed with CCC, IMP3 showed a better discrimination value than the other two markers. Consequently, adding IMP3 to the diagnostic panel might provide some help with the pathological diagnosis of ovarian CCC., (Copyright © 2018 The Authors. Published by Elsevier GmbH.. All rights reserved.)

Objective: Primary ovarian mucinous tumors progress from benign adenoma to borderline tumors to invasive mucinous carcinoma. A proper differential diagnosis is crucial to discriminate malignancies at the early stages of disease. However, few biomarkers are clinically available. We designed this study to analyze the clinical application of the oncogene IMP3 in monitoring early malignancies in ovarian primary mucinous tumors., Methods: We collected 250 samples of ovarian primary mucinous tumors along with the corresponding clinicopathological information between 2009 and 2015 at the Gynecology and Obstetrics Hospital of Fudan University and performed immunochemical assays. Statistical analysis of the correlation between expression of IMP3 and clinic-pathological parameters as well as the survivals of these patients was carried out. Finally, wound-healing and transwell assays were performed in SKOV3 and CAOV3 cells., Results: The expression rate and intensity of IMP3 were much higher in invasive carcinoma than those in benign adenoma and classic borderline adenoma ( P <0.05). The expression rate and intensity of IMP3 were also higher in cases with mucinous intraepithelial carcinoma than those in cases with classic borderline tumors ( P <0.05). Among the malignant cases, the expression rate and intensity of IMP3 increased with advancing FIGO staging ( P <0.05). The expression rate and intensity of IMP3 were much higher in cases with involved fallopian tubes, uterine and omentum than those in cases without the involvement of these tissues ( P <0.05). The expression rate and intensity of IMP3 were much higher in cases with lymph node metastasis than those in cases without lymph node metastasis ( P <0.05). Elevated expression of IMP3 significantly deteriorated the disease-free survival (DFS) and overall survival (OS) of mucinous carcinoma ( P <0.05). IMP3 was an independent risk factor of DFS but not OS. Further in vitro experiments indicated that IMP3 promoted the proliferation, motility and invasive potential of ovarian tumor cells., Conclusions: IMP3 is highly expressed in ovarian mucinous tumors and is positively correlated with malignancy. IMP3 could be used in the differential diagnosis of ovarian mucinous tumors and might be applicable in monitoring tumor initiation and progression., Competing Interests: None.

Objective: To clarify the clinicopathological features of ovarian clear cell carcinoma derived from endometriotic cyst (EC-OCCC)., Methods: Totally 54 cases of EC-OCCC were recruited in the current retrospective study. The relation between ages, clinical symptoms and signs, surgical and pathological stages, serum CA125, findings of ultrasound, treatments and the sites of tumors, macro- and micro-features and expression of immunostainings were analyzed., Results: (1) Clinical features: the ages of patients were (50±6) years old (range 31-62 years old). Pelvic mass was the major complaint of 50 patients (93% , 50/54). Forty-five cases belonged to International federation of Gynecology and Obstetrics (FIGO) stage I, 4 cases were stage II and another 5 cases were stage III. Serum CA125 was elevated in 21 cases (54%, 21/39) before therapy. Doppler ultrasound showed 46 cases (85%, 46/54) had solid masses in pelvis. (2) Pathological findings: 52 cases (96%, 52/54) had their tumor unilaterally, and 2 cases (4%, 2/54) occurred bilaterally. The maximal diameters of endometriotic cyst (EC) ranged from 1.5 to 23.0 cm and maximal diameters of ovarian clear cell carcinoma (OCCC) components were from 0.5 to 12.0 cm. Fifty-one cases (94%, 51/54) had their tumor within EC, which showed focally irregular protrudings, grey-white papillae or solid nodules attached to the cyst wall. Three cases (6%, 3/54) appeared as irregular thickened wall of the cysts, ranged from 1.5 to 6.0 cm in the maximal length, with the microscopic features of EC and OCCC and the transitional areas between the 2 morphologies. All cases expressed cytokeratin (CK) 7 and pan-CK AE1/AE3, 17 cases (33%, 17/51) expressed ER and 5 cases (10%, 5/51) expressed PR. TP53 showed mutational phenotype in 19 cases (36%, 19/53). Sixteen cases (30%, 16/54) combined with uterine adenomyosis and 25 cases (46%, 25/54) with endometriosis at other sites. (3) Survival survey: during the period of 39.1 months follow-up, 3 cases relapsed and 2 cases died. (4) There was a significant difference of serum CA125 between patients of early-and advanced-stages (P=0.049). There were no differences identified in ages, diameters of EC and OCCC, the expression level of ER, PR and TP53, the co-existence of adenomyosis and endometrosis, as well as ultrasonic findings (P>0.05)., Conclusion: EC-OCCC could be recognized in early stage by symptoms and ultrasound due to accompanied endometriotic cysts, resulting in relatively good prognosis.